SCHEMBL3209937

SCHEMBL3209937

CNC(=O)c1nc(Cc2ccccc2)nc2ccccc12

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PRNP P04156 3/20 0.54
RXFP1 Q9HBX9 3/20 0.54
NPSR1 Q6W5P4 1/20 0.54
L3MBTL1 Q9Y468 4/20 0.52
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
MAPT P10636 2/20 0.49
ALDH1A1 P00352 1/20 0.48
LMNA P02545 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
BRD4 O60885 3/20 0.48
POLB P06746 1/20 0.46
AURKA O14965 1/20 0.44
AURKB Q96GD4 1/20 0.44
ADORA3 P0DMS8 2/20 0.44
MAPK1 P28482 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3075260 0.77 ADORA3 (0.70) MEN1KMT2AALDH1A1ADORA3
SCHEMBL3209944 0.73 BRD4 (0.48) PRNPRXFP1NPSR1L3MBTL1BRD4
SCHEMBL13273004 0.72 NR1H2 (0.47) ALDH1A1BRD4POLBAURKA
SCHEMBL28211667 0.71 L3MBTL1 (0.60) PRNPRXFP1NPSR1L3MBTL1MEN1
SCHEMBL7044638 0.71 PDE10A (0.51) NPSR1L3MBTL1MEN1KMT2AMAPT
SCHEMBL31682474 0.71 L3MBTL1 (0.60) PRNPRXFP1NPSR1L3MBTL1MEN1
SCHEMBL16664897 0.70 RAB9A (0.50) MEN1KMT2AMAPTALDH1A1LMNA
SCHEMBL28189562 0.69 L3MBTL1 (0.58) PRNPRXFP1NPSR1L3MBTL1MEN1
SCHEMBL5127890 0.69 EGLN1 (0.52) KMT2AALDH1A1LMNA
SCHEMBL28260509 0.69 PLK1 (0.66) KMT2ALMNABRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8501754-B2 Quinazolinamide derivatives MERCK PATENT GMBH (DE) 2013-08-06 US disclosed
US-20100234324-A1 Quinazolinamide derivatives MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234324-A1 Quinazolinamide derivatives HSP90AB1, HSP90AA1, HSP90AB2P PRNP 656/4885RXFP1 2448/4885NPSR1 2343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.